Neuraxis, Inc. Total Assets
Neuraxis, Inc. total assets. Based on the latest financial reports, Neuraxis, Inc. (NRXS) holds total assets worth $8.75 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Neuraxis, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Neuraxis, Inc. (2020–2025)
Total assets of Neuraxis, Inc. from 2020 to 2025. This chart illustrates how Neuraxis, Inc.'s total assets have evolved over time, based on quarterly financial data. See NRXS stock price for real-time trading data and today's change.
Neuraxis, Inc. - Asset Composition Analysis
Neuraxis, Inc. Total Assets Breakdown (December 2025)
Neuraxis, Inc. total assets breakdown as of December 2025. Neuraxis, Inc.'s total assets of $8.75 Million consist of 89.5% current assets and 10.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 77.5% |
| Accounts Receivable | $195.70K | 3.1% |
| Inventory | $257.13K | 4.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $274.78K | 4.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Neuraxis, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NRXS working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuraxis, Inc.'s current assets represent 89.5% of total assets in 2025, an increase from 88.3% in 2020.
- Cash Position: Cash and equivalents constituted 77.5% of total assets in 2025, up from 68.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 4.3% of total assets.
Neuraxis, Inc. Competitors by Total Assets
Key competitors of Neuraxis, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Neuraxis, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.89 | 1.21 | 0.34 |
| Quick Ratio | 2.81 | 1.19 | 0.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.33 Million | $439.82K | $-933.85K |
Neuraxis, Inc. - Advanced Valuation Insights
This section examines the relationship between Neuraxis, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 27.78 |
| Latest Market Cap to Assets Ratio | 13.26 |
| Asset Growth Rate (YoY) | 34.6% |
| Total Assets | $6.40 Million |
| Market Capitalization | $84.91 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Neuraxis, Inc.'s assets at a significant premium (13.26x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Neuraxis, Inc.'s assets grew by 34.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neuraxis, Inc. (2020–2025)
The table below shows the annual total assets of Neuraxis, Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.40 Million | +34.61% |
| 2024-12-31 | $4.76 Million | +833.78% |
| 2023-12-31 | $509.50K | -65.59% |
| 2022-12-31 | $1.48 Million | +94.70% |
| 2021-12-31 | $760.48K | -72.74% |
| 2020-12-31 | $2.79 Million | -- |
About Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional … Read more